West Pharmaceutical Services Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $390.69
- Today's High:
- $396.385
- Open Price:
- $394.66
- 52W Low:
- $205.6593
- 52W High:
- $415.73
- Prev. Close:
- $397.15
- Volume:
- 239361
Company Statistics
- Market Cap.:
- $28.93 billion
- Book Value:
- 37.168
- Revenue TTM:
- $2.87 billion
- Operating Margin TTM:
- 24.51%
- Gross Profit TTM:
- $1.14 billion
- Profit Margin:
- 18.1%
- Return on Assets TTM:
- 12.49%
- Return on Equity TTM:
- 20.06%
Company Profile
West Pharmaceutical Services Inc had its IPO on 1978-01-13 under the ticker symbol WST.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. West Pharmaceutical Services Inc has a staff strength of 10,700 employees.
Stock update
Shares of West Pharmaceutical Services Inc opened at $394.66 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $390.69 - $396.39, and closed at $393.82.
This is a -0.84% slip from the previous day's closing price.
A total volume of 239,361 shares were traded at the close of the day’s session.
In the last one week, shares of West Pharmaceutical Services Inc have slipped by -3.4%.
West Pharmaceutical Services Inc's Key Ratios
West Pharmaceutical Services Inc has a market cap of $28.93 billion, indicating a price to book ratio of 7.1615 and a price to sales ratio of 6.0336.
In the last 12-months West Pharmaceutical Services Inc’s revenue was $2.87 billion with a gross profit of $1.14 billion and an EBITDA of $829 million. The EBITDA ratio measures West Pharmaceutical Services Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, West Pharmaceutical Services Inc’s operating margin was 24.51% while its return on assets stood at 12.49% with a return of equity of 20.06%.
In Q2, West Pharmaceutical Services Inc’s quarterly earnings growth was a negative -16.9% while revenue growth was a negative 2.3%.
West Pharmaceutical Services Inc’s PE and PEG Ratio
- Forward PE
- 28.8184
- Trailing PE
- 56.9215
- PEG
- 4.0596
Its diluted EPS in the last 12-months stands at $6.88 per share while it has a forward price to earnings multiple of 28.8184 and a PEG multiple of 4.0596. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into West Pharmaceutical Services Inc’s profitability.
West Pharmaceutical Services Inc stock is trading at a EV to sales ratio of 5.9352 and a EV to EBITDA ratio of 19.9417. Its price to sales ratio in the trailing 12-months stood at 6.0336.
West Pharmaceutical Services Inc stock pays annual dividends of $0.75 per share, indicating a yield of 0.19% and a payout ratio of 9.63%.
Balance sheet and cash flow metrics
- Total Assets
- $3.67 billion
- Total Liabilities
- $511.60 million
- Operating Cash Flow
- $-82100000.00
- Capital Expenditure
- $75.40 million
- Dividend Payout Ratio
- 9.63%
West Pharmaceutical Services Inc ended 2024 with $3.67 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.67 billion while shareholder equity stood at $2.75 billion.
West Pharmaceutical Services Inc ended 2024 with $36.00 million in deferred long-term liabilities, $511.60 million in other current liabilities, 18800000.00 in common stock, $3.25 billion in retained earnings and $108.00 million in goodwill. Its cash balance stood at $796.30 million and cash and short-term investments were $796.30 million. The company’s total short-term debt was $18,400,000 while long-term debt stood at $205.60 million.
West Pharmaceutical Services Inc’s total current assets stands at $1.87 billion while long-term investments were $202.80 million and short-term investments were $0. Its net receivables were $534.40 million compared to accounts payable of $218.00 million and inventory worth $449.40 million.
In 2024, West Pharmaceutical Services Inc's operating cash flow was $-82100000.00 while its capital expenditure stood at $75.40 million.
Comparatively, West Pharmaceutical Services Inc paid $0.10 in dividends in 2024.
Other key metrics
- Current Trading Price
- $393.82
- 52-Week High
- $415.73
- 52-Week Low
- $205.6593
- Analyst Target Price
- $383.63
West Pharmaceutical Services Inc stock is currently trading at $393.82 per share. It touched a 52-week high of $415.73 and a 52-week low of $415.73. Analysts tracking the stock have a 12-month average target price of $383.63.
Its 50-day moving average was $387.49 and 200-day moving average was $328.53 The short ratio stood at 2.05 indicating a short percent outstanding of 0%.
Around 53.7% of the company’s stock are held by insiders while 9621.2% are held by institutions.
Frequently Asked Questions About West Pharmaceutical Services Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.